A pre-specified subgroup analysis from the two replicate Phase III INPULSIS™ trials, presented at the European Respiratory Society International Congress (ERS), showed nintedanib* slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF), independent of severity of lung function impairment at baseline.1
IPF is a debilitating and fatal lung disease, with a median survival of 2–3 years after diagnosis.[i] It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and difficulty breathing.[ii]
The pooled analysis of INPULSIS™ data looked at annual decline in lung function in two pre-specified groups – baseline forced vital capacity (FVC) of >70% (n=700) and ≤70% predicted (n=361). The positive effect of nintedanib* on slowing disease progression was similar for both subgroups:1
- FVC >70% predicted: -111.3mL (nintedanib*) vs. -220.3mL (placebo), difference 109.0 mL (95% CI: 68.2, 149.9) in favour of nintedanib*.
- FVC ≤70% predicted: -119.7mL (nintedanib*) vs. -233.2mL (placebo), difference 113.5 mL (95% CI: 51.3, 175.7) in favour of nintedanib*.
The results for both subgroups are consistent with the INPULSIS™ primary endpoint finding for the overall patient population which showed nintedanib*, one capsule twice a day, slowed disease progression by reducing the annual rate of decline in lung function by 50% in a broad range of IPF patient types – including patients with
early disease (FVC>90% pred), no honeycombing on HRCT and/or concomitant emphysema.
“Nintedanib* is the first targeted treatment for IPF to consistently meet the primary endpoint in two identically designed Phase III trials and this sub-analysis further underscores its efficacy in IPF patients presenting different ranges of lung function impairment at baseline,” said Professor Ulrich Costabel, Ruhrlandklinik University Hospital, Germany
In a separate, additional analysis of the INPULSIS™ data, nintedanib* reduced the proportion of patients who experienced disease progression as measured by categorical (absolute or relative‡) FVC decline.2 A decline in FVC % predicted of >5% and >10% over 6 or 12 months in patients with IPF is a marker of disease progression and associated with reduced survival.3,[iv],[v],[vi],[vii],[viii],[ix]
Results showed:2
- In both INPULSIS™-1 and 2, significantly more patients taking placebo experienced an absolute decline in predicted FVC of >5%, as well as relative declines of >5% and >10% vs. nintedanib*.
- In INPULSIS™-1, significantly more patients in the placebo group experienced an absolute decline in predicted FVC of >10%; the difference in INPULSIS™-2 was numerically in favour of nintedanib* but did not reach statistical significance.
Further pre-specified sensitivity analyses of the INPULSISTM trials presented at the ERS meeting confirm the robustness of the primary and key secondary endpoint results for nintedanib* in IPF.[x]
In both INPULSIS™ trials, the most common adverse events were gastrointestinal in nature, of mild or moderate intensity, generally manageable and rarely leading to treatment discontinuation.5 The proportion of patients with serious adverse events was similar in all groups.5
“The results of these analyses further confirm and support the efficacy of nintedanib* on slowing disease progression in a wide range of patients with IPF,” said Dr Susanne Stowasser, Global Team Leader Medical Affairs, Boehringer Ingelheim. “Boehringer Ingelheim is committed to studying nintedanib* further and to making it available to patients with IPF and their treating physicians as soon as possible.”
[i]Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
[ii]Collard H, et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.
[iii] Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014 May; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584.
[iv] Collard HR, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538–42.
[v]King TE Jr, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171–7.
[vi] Latsi PI, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531–7.
[vii]du Bois RM, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382‒9.
[viii]Zappala CJ, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830‒6.
[ix]Jegal Y et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171;639–44.
[x] Kolb M, et al., Sensitivity analyses from the INPULSIS™ trials of nintedanib. Oral presentation at ERS International Congress, 8 Sept 2014.
